Compare Dollar Tree, Inc. (DLTR) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs 10X Genomics Inc — how do they compare? Dollar Tree, Inc. trades at $127.65 (market cap $24.86B), while 10X Genomics Inc trades at $58.6 (market cap $7.64B). The key difference: Dollar Tree, Inc. is far larger — about 3.3× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Dollar Tree, Inc. nearer its low. Which is the better fit depends on your goals.
| DLTR | TXG | |
|---|---|---|
Market Cap | $24.86B | $7.64B |
Sector | Health | Health |
52-Week High | $141.21 | $58.57 |
52-Week Low | $85.04 | $11.34 |
Enterprise Value | $31.45B | $7.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $130.9, up 0.94% on the day, with a bullish technical outlook and strong profitability metrics including a 34.71% ROE. Recent quarters have consistently beaten EPS estimates, and the company announced a $2.5 billion share repurchase authorization in July 2026. Revenue for 2025 was $17.58 billion, though net income was negative due to a significant tax charge, with a rebound to profitability projected for 2026.
The stock presents a mixed outlook: analyst consensus is a 'Buy' with a $129.08 price target near the current price, supported by solid cash flow and margin improvements. Key risks include competitive pressures, tariff impacts on margins, and execution of the turnaround strategy amid consumer spending shifts.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
